Literature DB >> 11435067

Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer.

A Försti1, J Louhelainen, M Söderberg, H Wijkström, K Hemminki.   

Abstract

Normal tumour-adjacent breast tissue samples from 12 breast cancer patients forming six monozygotic twin pairs were analysed for loss of heterozygosity (LOH) on chromosomes 1, 13 and 17. 7 patients showed LOH at one or more markers. Each of them had a different LOH pattern. Only one twin pair showed LOH at the same locus, but the twins had lost a different allele. Multiple (n=1-13), histologically normal samples were collected from 6 bladder cancer patients and analysed for LOH on chromosomes 3 and 9. On chromosome 9, all 6 patients analysed showed LOH in at least one sample and one marker. Four of them also showed LOH on chromosome 3. Samples surrounding different tumours of a given patient resembled each other. More heterogeneity was seen between the patients, even though they shared some similarities in LOH clustering. The results demonstrate that tumour-adjacent normal tissues already harbour genetic changes typical for tumours. These alterations can reveal the earliest changes leading to tumorigenesis.

Entities:  

Mesh:

Year:  2001        PMID: 11435067     DOI: 10.1016/s0959-8049(01)00118-6

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  21 in total

Review 1.  Open questions and novel concepts in oral cancer surgery.

Authors:  Giancarlo Tirelli; Serena Zacchigna; Matteo Biasotto; Marco Piovesana
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-24       Impact factor: 2.503

2.  Chemopreventive trials in urologic cancer.

Authors:  Vahagn R Ashughyan; Sibylle Marihart; Bob Djavan
Journal:  Rev Urol       Date:  2006

Review 3.  Genomic Changes in Normal Breast Tissue in Women at Normal Risk or at High Risk for Breast Cancer.

Authors:  David N Danforth
Journal:  Breast Cancer (Auckl)       Date:  2016-08-17

4.  Altered structure and deregulated expression of the tumor suppressor gene retinoblastoma (RB1) in human brain tumors.

Authors:  J Mathivanan; K Rohini; Mohan L Gope; B Anandh; Rajalakshmi Gope
Journal:  Mol Cell Biochem       Date:  2007-02-23       Impact factor: 3.396

5.  Fibronectin expression modulates mammary epithelial cell proliferation during acinar differentiation.

Authors:  Courtney M Williams; Adam J Engler; R Daniel Slone; Leontine L Galante; Jean E Schwarzbauer
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Selective regain of egfr gene copies in CD44+/CD24-/low breast cancer cellular model MDA-MB-468.

Authors:  Konstantin Agelopoulos; Burkhard Greve; Hartmut Schmidt; Heike Pospisil; Stefan Kurtz; Kai Bartkowiak; Antje Andreas; Marek Wieczorek; Eberhard Korsching; Horst Buerger; Burkhard Brandt
Journal:  BMC Cancer       Date:  2010-03-03       Impact factor: 4.430

7.  Genomic instability demonstrates similarity between DCIS and invasive carcinomas.

Authors:  Christopher M Heaphy; Marco Bisoffi; Nancy E Joste; Kathy B Baumgartner; Richard N Baumgartner; Jeffrey K Griffith
Journal:  Breast Cancer Res Treat       Date:  2008-09-11       Impact factor: 4.872

8.  Somatic acquisition of TGFBR1*6A by epithelial and stromal cells during head and neck and colon cancer development.

Authors:  Yansong Bian; Thomas J Knobloch; Maureen Sadim; Virginia Kaklamani; Adekunle Raji; Guang-Yu Yang; Christopher M Weghorst; Boris Pasche
Journal:  Hum Mol Genet       Date:  2007-09-21       Impact factor: 6.150

Review 9.  Evidence for field cancerization of the prostate.

Authors:  Larisa Nonn; Vijayalakshmi Ananthanarayanan; Peter H Gann
Journal:  Prostate       Date:  2009-09-15       Impact factor: 4.104

10.  Gene expression signatures of morphologically normal breast tissue identify basal-like tumors.

Authors:  Greg Finak; Svetlana Sadekova; Francois Pepin; Michael Hallett; Sarkis Meterissian; Fawaz Halwani; Karim Khetani; Margarita Souleimanova; Brent Zabolotny; Atilla Omeroglu; Morag Park
Journal:  Breast Cancer Res       Date:  2006       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.